Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CENTRAX vs CHLORDIAZACHEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Treatment of anxiety disorders,Short-term relief of anxiety symptoms,Off-label: insomnia, alcohol withdrawal, muscle spasm
Anxiety disorders,Acute alcohol withdrawal,Preoperative anxiety,Irritable bowel syndrome (off-label),Panic disorder (off-label)
10-30 mg orally, 3-4 times daily.
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Hepatic via CYP3A4; active metabolite desmethyldiazepam (nordazepam) with long half-life.
Chlordiazepoxide is metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. Its active metabolites include desmethylchlordiazepoxide, demoxepam, and nordazepam.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
98-99% bound to albumin.
90-98% bound to albumin and alpha-1-acid glycoprotein.
1.0-2.6 L/kg (mean 1.8 L/kg); extensive tissue distribution, indicating high lipophilicity and tissue sequestration.
0.5-0.8 L/kg; high Vd indicates extensive tissue distribution, with accumulation in adipose and brain tissue.
Oral: approximately 90-100%.
Oral: 90-100% (well absorbed); IM: 80-100% (but variable due to precipitation at injection site); IV: 100%.
GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose.
GFR 10-50 m L/min: administer 50-100% of usual dose; GFR <10 m L/min: administer 25-50% of usual dose.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
0.5-1 mg/kg/day in divided doses every 6-8 hours; maximum 40 mg/day.
Children 6-12 years: 5 mg orally 2-4 times daily, max 30 mg/day. Not recommended under 6 years.
Initiate at 5 mg 3-4 times daily; titrate cautiously due to increased sensitivity and risk of sedation.
Initial: 5 mg orally 1-2 times daily, increase cautiously; reduce total daily dose by 50% compared to younger adults.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Risk of dependence and withdrawal reactions; respiratory depression, especially with opioids; CNS depression; impaired psychomotor function; not recommended in severe hepatic impairment; use caution in elderly and debilitated patients.
Risk of dependence and withdrawal reactions,Potential for abuse and addiction,Respiratory depression, especially with concomitant CNS depressants,Central nervous system depressant effects, caution with impaired hepatic or renal function,Paradoxical reactions (e.g., agitation, aggression) in psychiatric patients,Suicidal ideation and behavior,Use in pregnancy: risk of neonatal sedation and withdrawal,Elderly patients: increased sensitivity and risk of falls
Hypersensitivity to benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; severe hepatic impairment; children <6 months; pregnancy (especially first and third trimesters).
Hypersensitivity to chlordiazepoxide or any benzodiazepine,Severe respiratory insufficiency,Sleep apnea syndrome,Severe hepatic impairment,Myasthenia gravis,Acute narrow-angle glaucoma,Concomitant use with ketoconazole, itraconazole, or other strong CYP3A4 inhibitors
Avoid grapefruit and grapefruit juice as they may increase prazepam levels. Limit caffeine intake as it may reduce sedative effects. No significant food restrictions apart from alcohol.
Avoid alcohol. No specific food interactions; take with or without food. Limit caffeine if it worsens symptoms.
First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, and neonatal respiratory depression. Avoid during pregnancy, especially in first and third trimesters.
First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless benefit justifies risk.
Prazepam and its active metabolite desmethyldiazepam are excreted in breast milk. M/P ratio not established. Potential for infant sedation and withdrawal. Use only if benefit outweighs risk.
Excreted in breast milk; M/P ratio 0.25-0.5. Potential for infant sedation, poor feeding. Avoid breastfeeding or use alternative therapy.
Pregnancy may increase clearance of benzodiazepines; consider dose adjustment based on clinical response. No standardized regimen; avoid use if possible.
Pregnancy may reduce plasma concentrations due to increased volume of distribution and enhanced clearance. Dose increases may be required, but avoid in pregnancy; if necessary, use lowest effective dose and limit duration.
CENTRAX (prazepam) is a long-acting benzodiazepine with a slow onset; not ideal for acute anxiety. Use with caution in elderly due to increased risk of falls and cognitive impairment. Avoid in severe hepatic impairment; consider dose reduction in mild-to-moderate hepatic disease. Monitor for tolerance and dependence; limit to short-term use (≤4 weeks). Do not discontinue abruptly; taper to prevent withdrawal seizures.
CHLORDIAZACHEL is a combination of chlordiazepoxide (benzodiazepine) and clidinium (anticholinergic). Used for peptic ulcer and irritable bowel syndrome. Monitor for CNS depression and anticholinergic effects (dry mouth, blurred vision, constipation). Avoid in glaucoma, urinary retention, and myasthenia gravis. Discontinue gradually to prevent withdrawal.
Avoid alcohol and other CNS depressants while taking this medication.,Do not drive or operate heavy machinery until you know how CENTRAX affects you.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking this medicine suddenly; your doctor will help you taper off.,Store at room temperature away from moisture and heat.,Report any suicidal thoughts or mood changes to your healthcare provider immediately.
Take exactly as prescribed; do not increase dose or duration.,Avoid alcohol and other CNS depressants.,May cause drowsiness; do not drive or operate machinery until effects are known.,Report bothersome side effects like constipation, dry mouth, or blurred vision.,Do not stop suddenly; taper under medical supervision.,Inform all healthcare providers you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CENTRAX vs CHLORDIAZACHEL, answered by our medical review team.
CENTRAX is a Benzodiazepine that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.. CHLORDIAZACHEL is a Benzodiazepine that works by Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CENTRAX and CHLORDIAZACHEL depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CENTRAX is: 10-30 mg orally, 3-4 times daily.. The standard adult dose of CHLORDIAZACHEL is: Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CENTRAX and CHLORDIAZACHEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CENTRAX is classified as Category C. First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, a. CHLORDIAZACHEL is classified as Category C. First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.